Rep. Lisa C. McClain Buys Chemed Corporation (NYSE:CHE) Shares

Key Points

• Representative Lisa C. McClain purchased shares of Chemed Corporation (NYSE:CHE) for between $1,001 and $15,000 on June 24th, 2023, through her Charles Schwab brokerage account.
• Chemed Corporation reported a missed earnings estimate with $4.27 earnings per share, falling short of the consensus estimate of $6.02, and had a revenue of $618.80 million compared to the expected $650.60 million.
• The company recently declared a quarterly dividend increase from $0.50 to $0.60 per share, set to be paid on August 29th, providing a yield of 0.5% based on an annualized amount of $2.40.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Chemed Corporation NYSE: CHE. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Chemed stock on June 24th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Chemed Stock Up 0.3%

NYSE CHE opened at $445.00 on Friday. The stock has a market capitalization of $6.48 billion, a P/E ratio of 22.88, a P/E/G ratio of 2.45 and a beta of 0.46. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60. The firm has a 50-day moving average price of $482.43 and a 200 day moving average price of $544.44.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($1.75). The firm had revenue of $618.80 million for the quarter, compared to analysts' expectations of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%. The company's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the company earned $5.47 earnings per share. On average, equities research analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 29th. Investors of record on Monday, August 11th will be issued a dividend of $0.60 per share. This is an increase from Chemed's previous quarterly dividend of $0.50. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, August 11th. Chemed's dividend payout ratio is currently 12.34%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Kayne Anderson Rudnick Investment Management LLC increased its stake in shares of Chemed by 2.6% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 597,175 shares of the company's stock worth $367,454,000 after purchasing an additional 15,041 shares in the last quarter. Neuberger Berman Group LLC boosted its position in Chemed by 3.9% during the first quarter. Neuberger Berman Group LLC now owns 521,212 shares of the company's stock worth $320,712,000 after acquiring an additional 19,650 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in Chemed by 5.1% during the fourth quarter. Epoch Investment Partners Inc. now owns 252,237 shares of the company's stock worth $133,635,000 after acquiring an additional 12,167 shares during the last quarter. Acadian Asset Management LLC boosted its position in Chemed by 69.3% during the second quarter. Acadian Asset Management LLC now owns 250,722 shares of the company's stock worth $122,056,000 after acquiring an additional 102,597 shares during the last quarter. Finally, Boston Trust Walden Corp boosted its position in Chemed by 0.4% during the second quarter. Boston Trust Walden Corp now owns 247,434 shares of the company's stock worth $120,483,000 after acquiring an additional 1,083 shares during the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CHE. Bank of America dropped their target price on shares of Chemed from $708.00 to $650.00 and set a "buy" rating for the company in a report on Monday, June 30th. Oppenheimer dropped their target price on shares of Chemed from $650.00 to $580.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Royal Bank Of Canada dropped their target price on shares of Chemed from $640.00 to $589.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Jefferies Financial Group began coverage on shares of Chemed in a report on Friday, July 25th. They issued a "hold" rating and a $500.00 target price for the company. Finally, Wall Street Zen cut shares of Chemed from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Chemed currently has an average rating of "Moderate Buy" and a consensus target price of $579.75.

Insider Buying and Selling

In related news, EVP Nicholas Michael Westfall sold 10,012 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $421.91, for a total transaction of $4,224,162.92. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George J. Walsh III bought 200 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The shares were purchased at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the transaction, the director owned 3,523 shares of the company's stock, valued at $1,469,443.30. The trade was a 6.02% increase in their position. The disclosure for this purchase can be found here. 3.29% of the stock is currently owned by company insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.